cervical cancer. Surgery and supportive Care is also available at the level of District Hospitals, Medical Colleges hospitals etc.

In the recent years the thrust of the National Cancer Control Programme (NCCP) has been on creating awareness and preventive activities for cancers including cervical cancer.

Violation of the Drugs and Cosmetics Act

2507. SHRI MOOLCHAND MEENA:
SHRI RAMA SHANKER KAUSHIK:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that DCGI has directed the withdrawal of products from the market and stoppage of production where the permissions were granted by the State Drugs Controller Authorities in violation of the Drugs and Cosmetics Act;

(b) whether it is also a fact that State Drugs Controller of Maharashtra had allowed the manufacture of Levonorgestrel 0.75 contraceptive for women for the new indication Emergency Contraception, which is a violation of Rule 122-E of the Drugs and Cosmetics Act; and

(c) the name of the company involved and the action taken against the erring authorities and the company?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRIMATI SUSHMA SWARAJ): (a) Yes, Sir.

(b) and (c) It was observed that the State Lincensing Authority, Maharashtra has allowed the manufacture of Levonorgestral 0.75 mg tablet as Emergency Contraceptive. As the use as Emergency Contraceptive in 0.75 mg strength is a new indication approved by DCG(I), M/s. Cipla was directed to stop marketing and obtain permission under the Rule-122 B from office of the DCG(I). Following submission of application in Form-44 alongwith requisite fees and other relevant data, the permission has been granted to the firm on 24.12.2002.